The term rhinitis implies a pathological diagnosis but the diagnosis is made clinically on the basis of the presence of two or more of the following symptoms for more than one hour on most days: sneezing, itching, rhinorrhoea and / or nasal obstruction (47). The nasal lining is continuous with that of the sinuses and so most patients with these symptoms have rhinosinusitis.
The International Rhinitis Management Working Group in their consensus report agreed three main aetiological groups: Allergic, Infective and another group of heterogeneous conditions. More than one aetiology may affect the individual patient.
This may be seasonal or perennial depending on the allergen involved. Seasonal allergic rhinitis due to grass pollens presents in May in the United Kingdom. Tree pollen allergy usually occurs earlier and weeds and moulds cause symptoms in summer and autumn. House dust mite and cat dander are the commonest causes of perennial allergic rhinitis.
This can be acute or chronic if symptoms persist beyond eight to twelve weeks. Acute rhinosinusitis is usually viral but when inflammation of the nasal lining impedes sinus ventilation / drainage through the region of the middle meatus (the so called ostiomeatal complex) secondary bacterial infection may develop.
1. Non-allergic, non-infective rhinosinusitis.
This group includes patients previously described by a sinus specialist as having intrinsic rhinitis, idiopathic rhinitis and vasomotor rhinitis. NARES (non-allergic rhinitis with eosinophilia) is also recognised (3). Some of these patients show a heightened sensitivity to non specific triggers such as humidity, air temperature and irritants and may complain of watery rhinorrhoea rather than blockage.
2. Rhinosinusitis with nasal polyps.
Nasal polyps can occur with cystic fibrosis (6,7) , asthma (8) and as part of a syndrome of aspirin sensitivity (9), but most commonly occur alone. The cause is unknown and while the prevalence of allergy is not higher in patients with polyps, mast cell reactions and eosinophil activation with subsequent inflammation seem to be implicated and explain why corticosteroids are therapeutically effective.
Pregnancy, puberty, hypothyroidism and acromegally are all associated with rhinosinusitis.
4. Rhinitis medicamentosa and drug - induced rhinitis
This condition may result from dependency on nasal decongestants. Beta blockers, NSAIDs and the oral contraceptive are other drugs commonly implicated.
5. Occupational rhinosinusitis
A variety of workplace chemicals - grain, wood-dusts and platinum salts for example - are known to cause a rhinosinusitis.
6. Atrophic rhinosinusitis
This is characterised by progressive atrophy of the sinonasal mucosa with viscid mucus which dries to fetid crusts. Klebsiella may be implicated but it may also result from over-aggressive nose plastic surgery with removal of excessive mucosa, Sjogren's syndrome, ageing and SLE.
Food can produce rhinosinusitis by a number of mechanisms (4). Gustatory rhinorrhoea (5) may occur when eating spicy foods. Specific allergic hypersensitivity reactions occur to particular foods ( or preservatives / colourants ) Alcohol produces a physiological vasodilatation and nasal congestion but can also provoke symptoms due to hypersensitivity. True food allergy is over-diagnosed and never causes isolated nasal symptoms.
8. Structural factors
Normal mucociliary clearance will be impaired where there is mucosal - mucosal contact - as in deviation of the nasal septum and concha bullosa and will result in neuropeptide mediated inflammation. These mechanical factors are amenable to corrective nose plastic surgery and are classified by some authors as a separate major diagnostic group.
Factors elicited in the history will help in determining the main aetiology. The chest and allergy deserve special attention. As well as eliciting specific nasal symptoms and their chronology, a thorough general medical history should be taken by the sinus specialist.
Examination by the sinus surgeon should include assessment of the external appearance of the nose and the anterior nasal septum to exclude structural deformities causing obstruction. Further assessment of the intranasal cavity may reveal polyps. Intranasal examination has been considerably enhanced with the advent of rigid and flexible endoscopes. The colour of the turbinates and mucus provide little diagnostic information.
1. Skin Prick Tests
Immediate hypersensitivity mediated by IgE can be demonstrated by skin-prick tests. They are preferred to scratch or intradermal tests which are less reproducible and more dangerous. However, the findings need careful interpretation in light of the clinical history as both false negative and false positive results occur (10) and there is little correlation between weal or flare size and symptoms (11). The majority of patients with allergic rhinitis are sensitive to a relatively small range of aeroallergens. A positive skin-prick test provides supportive evidence for the clinical diagnosis and is reassuring where costly or time-consuming allergen avoidance measures are suggested. It also re-inforces patient understanding.
2. Serum Specific IgE
When there is no extract for skin-prick testing, or skin-prick testing is not possible because of skin disease or the patient is on antihistamines specific serum IgE measurements can be made. (Radioallergosorbent-RAST test)
1. Plain Sinus Films
Plain radiographs have a limited role in the management of rhinosinusitis because they have such poor specificity and sensitivity (12). A positive finding of a fluid level in acute sinusitis may be helpful.
2. CT scans
CT scans provide important anatomical information if surgery is contemplated and demonstrate the extent of disease. There are false positives (48) but a clear scan is useful in excluding chronic sinonasal disease.
Guarded specimens obtained under direct endoscopic visualisation of the middle meatus correlate well with formal sinus aspirates, in contrast to blind nasal swabs.
In the specialist and research setting further investigations by the sinus specialist may help to determine a complex aetiology and assess treatment outcome. These include assessments of ciliary function, olfaction, and the nasal airway.
When symptoms are unilateral one should be suspicious of malignancy. Where there is watery rhinorrhoea one should consider a cerebrospinal fluid leak, especially if unilateral. Lower respiratory tract pathology such as Wegener's and sarcoidosis may also be associated with nasal and sinus manifestations.
Antihistamines act as competitive antagonists at the histamine receptor. They are effective in reducing established symptoms of sneezing, itching and watery rhinorrhoea in particular. Cetirizine, loratidine, acrivastine and terfenadine suppress skin reactions for about four days after drug ingestion whereas astemizole has a much longer half-life and reduces skin prick reactions for up to eight weeks (23). Cetirizine is unique in that it is not metabolised in the liver but excreted in the urine.
Reports (24,25) have associated astemizole and terfenadine with serious cardiac arrhythmias. This is because in high doses the delayed rectifier potassium channels are blocked prolonging the QT interval (26). The drugs are metabolised in the liver by the cytochrome P450 system and should therefore not be used in hepatic failure or together with competitors for the P450 system (such as macrolide antibiotics and antifungals). Fexofenadine, the active metabolite of terfenadine is free of this arrhythmogenic effect.
Though controversial it is likely that antihistamines exert an anti-inflammatory effect beyond that produced solely by antagonism of the H1 receptor. Certainly the production of adhesion molecules (ICAM-1), and the release of interleukin- 8 ( a neutrophil chemotactic and activating factor ) and granulocyte-macrophage colony stimulating factor from epithelial cells stimulated by activated eosinophils is reduced (27).
Comparitive studies between oral antihistamines are difficult to evaluate. Full dose-response curves have not been performed in the same individuals to compare efficacy and side effects. However the greater cost of the non-sedating antihistamines is substantially offset by the lack of effect on performance.
Topical antihistamines such as azelastine and levocabastine are available and can be used for acute symptomatic relief and prophylaxis of allergic rhinitis without systemic side effects.
Corticosteroids penetrate the cell membrane and bind to hormone receptors in the cytoplasm. Within the nucleus the steroid/receptor complex binds to specific DNA sites which have a regulatory role in protein synthesis. This is manifest in a reduction in inflammatory cell infiltration and its consequences (29).
Corticosteroids may be given topically, taken orally or adminstered intravenously.
Topical corticosteroids are effective in reducing nasal blockage, itching, sneezing and rhinorrhoea in allergic and non-allergic non-infective rhinosinusitis (34). Their ability to reduce nasal blockage and efficacy in non-allergic rhinitis gives them an advantage over antihistamines. They are more effective in symptomatic control of allergic rhinitis than sodium cromoglycate (35), antihistamines (36) and decongestants (37).
Numerous comparative studies have been performed but there are no published studies that show one nasal steroid is more effective than any other (eg 53,54,55). Therefore, choice of agent depends on patient preference and cost.
Beclomethasone was introduced in 1973 and combined high topical efficacy with rapid hepatic metabolism (28). Subsequently a variety of topical nasal steroid sprays have become available. These are: budesonide (rhinocort), flunisolide (syntaris), fluticasone (flixonase), mometasone (nasonex) and triamcinolone (nasocort). With the exception of beclomethasone and flunisolide they are once-a-day preparations.
Environmental concerns have led to the elimination of CFC driven aerosols. Topical corticosteroids are therefore administered by mechanical pump sprays in aqueous or glycol solutions or as a dry powder. There has been some concern that benzalkonium chloride, a preservative used in intranasal corticosteroid sprays, has toxic effects on cultured nasal epithelium (48) but this effect has not been demonstrated in vivo (49).
Of greater concern is the extent of systemic absorption and the effects on growth in children. Although there are few studies into the effects of topical nasal steroids there have been numerous ones into the effects of inhaled and oral steroids on growth. A meta-analysis performed in 1994 (30) indicates that while oral steroids do indeed reduce final height, the use of inhaled beclomethasone diproprionate does not appear to be associated with diminished stature even at twice the normal dose. However in a randomised double blind crossover study of 19 schoolchildren with mild asthma, treated by inhaled steroids, compared with fluticasone, use of beclamethasone was associated with a statistically significant reduction in lower leg growth velocity (38). The Committee on Safety of medicines and the Medicines Control Agency have concluded (50) that clinically important systemic adverse effects occur at licensed doses but in mitigation state: It is important to emphasise that inhaled ... corticosteroids provide proven, effective control of ... rhinitis ... and may in some patients remove the necessity for oral corticosteroid therapy. The recognition that systemic effects may occur, and that the lowest effective dose should be used, does not alter the favourable risk-benefit profile of these medicines. Topical nasal steroids are not recommended under the age of four.
Short courses of oral steroid can be used, perhaps immediately prior to or following surgery, but only with caution. Contraindications to treatment with systemic steroids include diabetes mellitus, gastric ulceration, osteoporosis, severe hypertension and herpes keratitis or other severe infection. Betamethasone sodium phosphate drops are also very effective in symptomatic relief of allergic and non-allergic non-infectious rhinosinusitis. They are however capable of producing minor systemic steroid effects so their longterm use cannot be recommended. Two drops of betamethasone to each nostril twice daily has been estimated to be equivalent to 1.15mg prednisolone daily (31). Proper drop insertion technique is crucial. Radiological studies and clinical evidence support the head down and forwards technique (32,33).
Sodium cromoglycate was first synthesised in 1965 and noted to cause a novel inhibition of degranulation of rat peritoneal mast cells (39). This gave rise to the concept of mast cell stabilisation. Although this action has been demonstrated in in-vitro studies of human lung mast cells and mast cells recovered by bronchoalveolar lavage (40), this mechanism does not seem to apply in mast cells recovered from nasal scrapings in rhinitis (41). Instead the effectiveness of the drug in this setting is attributed to its ability to influence granulocyte chemotaxis (42) and reduce endothelial adhesion molecule expression (43).
Sodium cromoglycate reduces nasal itching, sneezing, rhinorrhoea and blockage in allergic rhinitis. It has negligible side effects (burning sensation) but needs to be applied four times a day. It is primarily a prophylactic drug for use in children but is less effective than topical corticosteroids.
Cholinergic receptors are important in the production of nasal secretions but have no affect on nasal blockage, itching or sneezing (44). Ipratropium bromide is therefore useful in the treatment of patients with profuse rhinorrhoea but can cause local drying of the nasal mucosa which is minimised by allowing the patient to decide on the lowest effective dose (45).
The nasal administration of local vasoconstrictors is not usually recommended for more than 3-4 weeks because of the risk of rhinitis medicamentosa (51). However, used prior to other treatments for short periods they can be a useful adjunct to therapy.
As the mechanisms of rhinitis are elucidated and the roles of specific inflammatory mediators clarified new therapeutic strategies suggest themselves. For example leukotrienne receptor antagonists may prove helpful for aspirin sensitive patients who produce excessive leukotriennes and exhibit increased sensitivity to them Immunotherapy The efficacy of desensitisation is well documented in double blind controlled trials but can cause life-threatening reactions, especially in asthmatics. For this reason the practice has been significantly curtailed and in the UK asthmatics are specifically excluded from this treatment. Patients should only be desensitised by suitably trained physicians with adrenaline immediately available (46).
Specific immunotherapy is appropriate where pharmacotherapy inadequately controls the symptoms of allergic rhinitis or the side-affects are unacceptable or appropriate avoidance measures fail. There should be at least a six month history in perennial rhinitis or two season history in allergic rhinitis and positive skin tests or serum specific IgE which correlate with the symptoms.
Nose plastic surgery should be reserved for patients in whom medical treatment has failed.
When medical treatment has failed , numerous studies have found that surgery benefits at least 80% of patients. When surgery is indicated it should be directed at removing diseased mucosa ( including nasal polyps) and mucosal contact areas. This will help to drain the sinuses and allow aeration, facilitate the recovery of cilia and allow access for topical nasal medication.
Whilst nose plastic surgery surgery provides good symptomatic relief continued medical treatment and further surgery are often required.
Endoscopic surgery has the advantage that no external incision is required
Surgical procedures on the internal and external nasal structures to correct mechanical obstruction of the airway results in improvement in subjective nasal symptoms as well as objective measurements.
3. Jacobs R L, Fredman I M,Boswell R N. Non-allergic rhinitis with eosinophilia (NARES syndrome): clinical and immunological presentation. J Allergy Clin Immun1981: 67: 253-62.
4. Metcalfe D D. The diagnosis of food allergy: theory and practice. In Spector S, ed. Provocative challenge procedures: bronchial, oral, nasal and exercise. Vol 2. Boca Raton: CRC Press, 1983: 119-25.
5. Raphael G D, Hauptschein-Raphael M,Kaliner M. Gustatory rhinitis: a syndrome of food-induced rhinorrhoea. J Allergy Clin Immunol 1989: 83: 110-15.
6. Stern R C,Boat T F, Wood R E. Treatment and prognosis of nasal polyps in cystic fibrosis. Am J Dis Child1982: 136: 1067-70.
7. Disant Agnese P A, David P B. Cystic fibrosis in adults: 75 cases and areview of 232 cases in the literature. Am J Med 1979: 66: 121-32.
8. Drake-Lee A B, Lowe D, Swanston A, Grace A. Clinical profile and recurrence of nasal polyps. J Laryngol Otol 1984: 98: 783-93.
9. Harnett J C, Spector S L, Farr R S. Aspirin idiosyncracy, asthma and urticaria. In: Middleton E, Reed C E, Ellis E F, eds. Allergy: principles and practice. St Louis: C V Mosby, 1978: 1002-21.
10. Sampson H A. Comparitive study of commercial food antigen extracts for the diagnosis of food hypersensitivity. J Allergy Clin Immunol 1988; 82: 718-26.
11. van der Linden P G, Hack C E, Struyvenberg A, van der Zwan J K. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria do not predict the occurrence and severity of anaphylaxis. J Allergy Clin Immunol 1994; 94: 151-9.
12. The Royal College of Radiologists. Making the best use of a Department of Clinical Radiology. Third Edition. 1995. The Royal College of Radiologists. London. 1-96. ISBN: 1 872599 04 4.
17. Scadding G K. Nasal Symptoms. Update. 1997. March 268-276.
18. Sibbald B, Rink E. Epidemiology of seasonal and perennial Rhinitis: clinical presentation and medical history. Thorax. 1991. 46,895-901. 19. Juniper E F, Guyatt G H. Development and testing of a new measure of health statusfor clinical trials in rhinoconjunctivitis.
20. Fireman P. Treatment of allergic rhinitis: Effect on occupation productivity and work force costs. Allergy and Asthma Proc. 1997. 18 (2) 63-67.
21. Weiner M J, Abramson M J, Puy R M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised control trials. BMJ 1998: 317: 1624-1629.
22. Calderon-Zapata M A, Davies R J. Treatment and management of allergic rhinitis. In: Kay A B, ed. Allergy and allergic diseases. Oxford: Blackwell, 1997.
23. Felderman R B, Rosen L J. Comparison of the onset and offset of inhibition of antigen induced skin whealing of terfenadine, astemizole and placebo. J Allergy Clin Immunol 1987: 79: 190-4.
24. Craft T M. Torsade de pointes after astemizole overdose. BMJ 1986;292: 660.
25. Monahan B P et al. Torsade de pointes occuring in association with terfenadine use. JAMA 1991;266: 2375-6.
26. Rampe D et al. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from the human heart. Mol Pharmacol 1993;44: 1240-5.
27. Abdelaziz M M et al. Effect of fexofenadine on eosinophil induced changes in epithelial permeability and mediator release from nasal epithelial cells of seasonal allergic rhinitics. J Allergy Clin Immunol 1997
28. Mygind N. Local effect of intranasal beclomethasone diproprionate aerosol in hay fever. BMJ 1973: 4: 464-6.
29. Minshall E, Ghaffar O, Cameron L, O`Brien F, Quinn H, Rowe-Jones J, Davies R J, Prior A, Lund V J, Mackay I S, Nolop K, Lutsky B, Durham S R, Hamid Q. Assessment by nasal biopsy of long-term use of mometasone aqueous nasal spray in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118: 648-54.
30. Allen D B, Mullen M, mullen B. 1994. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994; 93(6): 967-76
31. Mackay I. ed. (1989) Topical medical management of allergic conditions of the nose. Part 2: Intranasal steroids. In: Rhinitis . Mechanisms and management. London: Royal Society of Medicine Services Limited. pp183-204
32. Charlton R, Mackay I, Wilson R, Cole P. Double-blind placebo controlled trial of betamethasone nasal drops for nasal polyposis. BMJ 1985; 291: 788.
33. Wilson R, Sykes D, Chan K, Cole P, Mackay I. The effect of head position on the efficacy of topical treatment of chronic mucopurulent rhinosinusitis. Thorax 1987; 42: 631-2
34. Orgel H A, Meltzer E O, Bierman W et al. Intranasal fluocortin butyl in patients with perennial rhinitis: a 12-month efficacy and safety study including nasal biopsy. J Allergy Clin Immunol 1991:88: 257-64.
35. Welsh P W, Stricker W E, Chu-Pin C, et al. Efficacy of beclomethasone nasal solution, flunisolide and cromlyn in relieving symptoms in ragweed allergy. May Clin Proc 1987: 62: 125-34.
36. Harding S M, Heath S. Intranasal steroid aerosol in perennial rhinitis: comparison with antihistamine compound. Clin Allergy 1976: 6: 369-72.
37. Juniper E F, Kline P A, Hargreave F E, Dolovich J. Comparison of beclomethasone diproprionate aqueous nasal spray, astemizole and the combination in prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989: 83: 627-33.
38. Wolthers O D, Pederson S. Short-term growth during treatment with inhaled fluticasone proprionate and beclomethasone diproprionate. Arch Dis Child. 1993: 68(5): 673-6.
39. Cos J. Disodium cromoglycate (FPL 670 "intal") : a specific inhibitor of reaginic antigen-antibody mechanisms. Nature (London) 1967; 216: 1328-9.
40. Pearce F L, Al_Laith M, Bosman L, et al. Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from various locations. Drugs 1989; 37 (suppl): 37-43.
41. Okuda M, Ohnishi M, Ohtsuka H. The effect of cromolyn sodium on the nasal mast cells. Ann Allergy 1985; 55: 721-3.
42. Kay A B, Walsh G M, Moqbel R, et al. Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. J Allergy Clin Immunol.1987; 80: 1-8.
43. Klein L M, Larker R M, Matis W L, Murphy G F. Degranulation of human mast cells induces an endothelial antigen central to leucocyte adhesion. Proc Natl Acad Sci 1989; 86: 8972-6.
44. Borum P, Mugind N, Schultz Larsen F. Intranasal ipratropium: a new treatment for perennial rhinitis. Clin Otolaryngol 1979; 4: 407-11.
45. Dolovich J, Kennedy L, Vickerson F, Kazim F. Control of the hypersecretion of vasomotor rhinitis by topical ipratropium bromide. J Allergy Clin Immunol 1987; 80: 274-8.
46. Malling H J, Weeke B. EAACI Position Paper. Immunotherapy. Allergy 1993: 48 (suppl. 14): 1-35.
47. International Rhinitis Management Working Group. International Consensus Report on the Diagnosis and management of Rhinitis. Allergy 1994: 49 (supp. 19): 1-30.
48. Steinsvag S K, Bjerknes R, Berg O H. Effects on human respiratory mucosa and human granulocytes of decongestive nosedrops and topical nasal steroids in vitro. Abstract-book EAACI. Rotterdam 1993: 22 (no. 1083).
49. Braat J P M, Ainge G, Bowles J A K, Richards D H, van Riessen D, Visser W J and Rijntjes E. The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: a combined functional, light, scanning and transmission electron microscopy study. Clinical and Experimental Allergy 1995: 25: 957-65.
50. Current Problems in Pharmacovigilance, Focus on Corticosteroids. May 1998: 24: 5-10.
51. Yoo J K, Seikaly H, Calhoun K H. Extended use of topical nasal decongestant. Laryngoscope. 1997 107 (1): 40-43.
52. Statements of Clinical Effectiveness in Otolaryngology 1998. British Association of Otolaryngologists Head and neck Surgeons.
53. Scadding G K, Lund V J, Jacques L A and Richards D H. A placebo controlled study of fluticasone proprionate aqueous nasal spray and beclomethasone diproprionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clinical and Experimental Allergy, 1995, Volume 25, 737-43.
54. Mandl M, Nolop K and Lutsky B. Comparison of once daily mometasone furoate and fluticasone proprionate aqueous nasal sprays for the treatment of perennial rhinitis. Annals of Allergy, Asthma and Immunology. Oct 1997, volume 79, No 4, 370-8.
55. Haye R, Gomez E. A multicentre study to assess long-term use of fluticasone proprionate aqueous nasal spray in comparison with beclomethasone diproprionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology. 1993. 31,169-74.